SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Etiology and Risk Factors for Developing Orthostatic Hypotension

By 1 Comment

Skip Navigation Links
American Journal of Therapeutics:

January/February 2010 – Volume 17 – Issue 1 – pp 86-91
doi: 10.1097/MJT.0b013e3181a2b1bb
Therapeutic Review

Mosnaim, Aron D PharmD, PhD; Abiola, Rasheed BS; Wolf, Marion E MD; Perlmuter, Lawrence C PhD

Orthostatic hypotension (OH) is regarded as a decrease primarily in systolic blood pressure on changing position from supine to erect. Based on clinical criteria, it is characterized by a decrease in systolic pressure of 20 mmHg and diastolic pressure of 10 mmHg within 1 to 3 minutes of standing after being supine. It is most prevalent in, although not limited to, the elderly population and is characterized by a variety of problems, including diminished cognition and disturbed emotion along with gate problems, falls, and brain and cardiovascular difficulties.

Ampiginous choroiditis following quadrivalent human papilloma virus vaccine

By Leave a Comment

Case report

A 17-year-old female was referred for new-onset vision loss in both eyes 3 weeks after being vaccinated with the quadrivalent HPV vaccine. A standard dose of 0.5 ml was injected intramuscularly into the left deltoid without any resulting skin reaction. Her medical history was significant for depression treated with quetiapine. Three weeks following vaccination, she developed painless vision loss in the left eye …

Human Papillomavirus Vaccination of Males: Attitudes and Perceptions of Physicians Who Vaccinate Females

By Leave a Comment

The Body

The Complete HIV/AIDS Resource
September 14, 2010

The authors assessed US physicians’ attitudes and perceptions regarding potential human papillomavirus vaccination of males in a random sample of 2,714 pediatricians and family practitioners identified in administrative claims of a US health plan as HPV vaccinators of females.

Of the 595 pediatricians and 499 family practitioners who participated, most said they would recommend HPV vaccination to males ages 11-12 (63.9 percent), 13-18 (93.4 percent), and 19-26 (92.7 percent) years. Physicians agreed that males should be vaccinated to prevent transmission of genital and anal warts (52.9 percent strongly, 36.0 percent somewhat) and to protect females from cervical cancer (75.3 percent strongly, 20.8 percent somewhat).

More than HPV: Vaccines Against Cancer

By Leave a Comment

Meetings of Nobel Laureates Lindau from Jessica Riccò, 28. June 2010, 18:25 The late morning in Lindau was a non-stop marathon of medical researchers – first Harald zur Hausen talked about the links between infections and cancer, then Luc Montagnier gave an insight into his research that analyzes DNA under physical as well as biological […]

Professor Frazers excellent adventure

By 1 Comment

Australian Doctor

16 November 2005

An unglamorous quest to discover why HIV-positive men were plagued with anal warts led Professor Ian Frazer to a hugely lauded scientific discovery — a vaccine against cervical cancer. By Bianca Nogrady.

PROFESSOR Ian Frazer radiates energy, albeit an energy tinged with impatience. He may be enthusiastic and talkative throughout this umpteenth media interview, but you can tell he really just wants to get back to his work.

That’s understandable — after all, not only has he led research that could eliminate the spectre of cervical cancer, but he is now on the verge of another breakthrough that has some touting him as Australia’s next Nobel laureate.

Described as “the common cold of sexual activity”, HPV infects an estimated 630 million women around the world, indirectly claiming the lives of about 288,000 each year.

News

Videos

Contact